Integrilin Solution For Injection 0.75Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Integrilin: Solution for injection (0.75mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

EPTIFIBATIDE (ep TIF i ba tide) prevents your blood from clotting during episodes of chest pain or a heart attack. This medicine may also be used to prevent blood clots during a procedure to treat a blocked heart artery.

In-Depth Information
Select a Medication

Integrilin 75mg/100ml Solution for Injection (PREMIER ProRx)

NDC: 000851136
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Myocardial Infarction Prophylaxis, Percutaneous Coronary Intervention (PCI), Unstable Angina, Acute Myocardial Infarction, NSTEMI

Sometimes used for but not FDA approved for the following conditions:
Acute Myocardial Infarction, STEMI

Storage Information
May be stored at room temperature not exceeding 86 degrees F for up to 2 months
Refrigerate (between 36 and 46 degrees F)
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Discard unused portion. Do not store for later use.
Integrilin 75mg/100ml Solution for Injection (PREMIER ProRx)

Reported Side Effects for Integrilin 75mg/100ml Solution for Injection (PREMIER ProRx)

Severe Allergy Incidence:
0.2%*
Severity: SEVERE
Onset: RAPID
Anaphylactoid Reactions Incidence:
0.2%*
Severity: SEVERE
Onset: RAPID
Brain Attack Incidence:
0.5-0.7%*
Severity: SEVERE
Onset: EARLY
Low Platelet Count Incidence:
1.2%*
Severity: MODERATE
Onset: DELAYED
Bleeding Incidence:
1.3-14.2%*
Severity: MODERATE
Onset: EARLY
Low Blood Pressure Incidence:
7.0%*
Severity: MODERATE
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Integrilin

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5